WO2011149126A1 - 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 - Google Patents
타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2011149126A1 WO2011149126A1 PCT/KR2010/003332 KR2010003332W WO2011149126A1 WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1 KR 2010003332 W KR2010003332 W KR 2010003332W WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- tyrosine kinase
- kinase inhibiting
- inhibiting function
- inflammatory compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
본 발명은 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 유효성분으로 함유하는 약학적 조성물에 관한 것으로, 본 발명에 따른 화합물은 여러 타이로신 카이네이즈들의 활성을 억제할 수 있어, 이와 관련된 염증성 질환이나 자가면역질환 등을 예방 또는 치료하는데 유용하게 사용될 수 있다.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (ko) | 2010-05-26 | 2010-05-26 | 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 |
JP2013512543A JP5613323B2 (ja) | 2010-05-26 | 2011-05-26 | 複数のチロシンキナーゼに対する阻害活性を有する抗炎症化合物およびこれを含む薬学的組成物 |
PCT/KR2011/003873 WO2011149288A2 (ko) | 2010-05-26 | 2011-05-26 | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 |
KR1020127030670A KR101478302B1 (ko) | 2010-05-26 | 2011-05-26 | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 |
EP11786920.6A EP2578590B1 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
CN201180026042.7A CN102971327B (zh) | 2010-05-26 | 2011-05-26 | 具有多种酪氨酸激酶抑制活性的抗炎化合物以及含有这些化合物的药物组成物 |
HUE11786920A HUE035589T2 (en) | 2010-05-26 | 2011-05-26 | An anti-inflammatory compound having an anti-tyrosine kinase inhibitory activity and a pharmaceutical composition containing it |
ES11786920.6T ES2647586T3 (es) | 2010-05-26 | 2011-05-26 | Compuesto antiinflamatorio que tiene actividad inhibidora contra múltiples tirosina cinasas, y composición farmacéutica que contiene el mismo |
US13/699,970 US9062066B2 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
DK11786920.6T DK2578590T3 (da) | 2010-05-26 | 2011-05-26 | Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende samme |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (ko) | 2010-05-26 | 2010-05-26 | 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011149126A1 true WO2011149126A1 (ko) | 2011-12-01 |
Family
ID=45004106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (ko) | 2010-05-26 | 2010-05-26 | 타이로신 카이네이즈 저해능을 가지는 항염증 화합물을 포함하는 약학적 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011149126A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492383B1 (en) * | 1997-11-11 | 2002-12-10 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
-
2010
- 2010-05-26 WO PCT/KR2010/003332 patent/WO2011149126A1/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492383B1 (en) * | 1997-11-11 | 2002-12-10 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
Non-Patent Citations (1)
Title |
---|
BOSCHELLI, D.H. ET AL.: "Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)-amino]-2-heteroaryl-thieno[3,2-b] pyridine-6-carbonitriles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 4681 - 4684 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012046030A3 (en) | Phosphodiesterase inhibitors | |
WO2011162515A3 (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
WO2008094737A3 (en) | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
WO2012021715A3 (en) | Stable formulations of linaclotide | |
MX2010014041A (es) | Una forma cristalina de posaconazol. | |
WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
WO2013185082A3 (en) | Inhibitors of bruton's tyrosine kinase | |
NZ745210A (en) | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor | |
WO2012101653A3 (en) | Modified release pharmaceutical compositions memantine | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
WO2011149288A2 (ko) | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 | |
WO2011126250A3 (ko) | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 | |
WO2014141210A3 (en) | Multifunctional immature dental pulp stem cells and therapeutic applications | |
WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
WO2011141488A3 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
WO2011159137A3 (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
WO2014160775A8 (en) | Compositions and methods for the treatment of malaria | |
AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
WO2011149301A3 (en) | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases | |
WO2011150457A3 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
WO2011088160A3 (en) | Novel cyp17 inhibitors | |
MX344189B (es) | Formulaciones de mazindol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10852212 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.03.2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10852212 Country of ref document: EP Kind code of ref document: A1 |